| Literature DB >> 273713 |
M N Huang, H Takita, H O Douglass.
Abstract
Osteogenic sarcoma, excluding the paraosteal osteosarcoma, has a grave prognosis, half of the patients dying within 1 year following ablative surgery of the primary lesion. Once pulmonary metastasis is detected, most patients do not survive more than 3 years. Various attempts by investigators to prolong patient survival, including surgery, chemotherapy, immunotherapy, radiation therapy, and combined modalities, have met with some success. This report is a summary of 13 patients who underwent lung resections and received adjuvant chemo- and/or immunotherapy for metastatic osteogenic sarcoma in our intstitute in the past 7 years.Entities:
Mesh:
Substances:
Year: 1978 PMID: 273713 DOI: 10.1002/jso.2930100210
Source DB: PubMed Journal: J Surg Oncol ISSN: 0022-4790 Impact factor: 3.454